Table 1.
Clinical Trials.
Code | N° Subjects | Cancer Type | Finding | Ref. |
---|---|---|---|---|
NCT0272428 | 12,741 | all | ↓incidence in men (7,5 yr.) | Hercber et al. [48] |
NCT00270647 | 14,641 | all | ↓re-incidence in men (11 yr.) | Gaziano et al. [49] |
Eudra-CT2019-004074-25/ NCT01080352 |
20 | prostate | Media-severe side effects | Nielsen et al. [52] |
NCT0105062 | 14 | all | ↓symptoms/progression (43%) | Hoffer et al. [54] |
NCT00006021 | 22 | myeloma | ↓progression (50%) | Bahlis et al. [55] |
NCT01515046/ NCT01049880 |
9 | pancreas | ↑survival (12 mo.) | Welsh et al. [56] |
NCT01364805 | 14 | pancreas | ↓metastasis and cell proliferation | Polireddy et al. [57] |
NCT00954525 | 14 | pancreas | ↓tumor size | Monti et al. [58] |